Pharmaceutical Cooperation Cutis Pharma and Dr. Reddy's Laboratories Announce Partnership

Editor: Dominik Stephan

Cutis Pharma, a specialty pharmaceutical company that has entered into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr Reddy’s advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

Related Companies

(Picture: Public Domain Pictures (CC0))

Wilmington, Massachusetts/USA – “This partnership has significant strategic benefits for both parties,” said Neal Muni, MD, MSPH, Chief Executive Officer of Cutis Pharma. “Dr. Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”

Deepak Sapra, Vice President & Global Head, CPS Business of Dr. Reddy’s Laboratories, said, “We continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with Cutis Pharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”

“By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the United States as well as select international markets.” Muni said.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent